A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
This study is for the treatment of metastatic hormone-sensitive prostate cancer.
Study phase: III
Primary disease category: Cancer
Secondary disease categories: Cancer, Prostate Cancer
Sponsor: Southwest Oncology Group
Protocol number: S1216
Projected enrollment dates: July 2013 to July 2020
Official study title: S1216 A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT01809691